Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
NOD-like Receptor (NLR) Inhibitor
Apilimod hydrochloride is an inhibitor of the PIKFYVE kinase, targeting the NOD-like receptor (NLR) pathway. This compound facilitates the activation of NLRP3 inflammatory vesicles and promotes the secretion of IL-1β. Its ability to inhibit host cell proteases may prevent viral invasion; however, it may also obstruct antiviral immune responses, which could lead to increased immunosuppression in conditions such as COVID-19. Research applications include studies on inflammation, immune response regulation, and viral pathogenesis. -
NLRP3 Inflammasome Inhibitor
YM-I-26 is a selective inhibitor of the NLRP3 inflammasome, effectively modulating inflammatory responses. It enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells while concurrently inhibiting the secretion of pro-inflammatory cytokines IL-1β and IL-10. This compound is useful for investigating the role of the NLRP3 inflammasome in various inflammatory conditions and its potential as a therapeutic target in immune modulation. -
NLRP3 Inhibitor
Isoandrographolide is a selective inhibitor of the NLRP3 inflammasome, known for its potential to modulate inflammatory responses. This compound exhibits significant hepatoprotective effects and promotes cell differentiation. Research applications include studying the role of NLRP3 in inflammatory diseases and exploring therapeutic strategies for conditions such as silicosis. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury. -
NLRP3 Inhibitor
NLRP3-IN-27 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 0.55 μM. This compound is instrumental in investigating the role of NLRP3 in inflammatory processes and immune response modulation. It is a valuable tool for researchers studying the molecular mechanisms of inflammation and potential therapeutic strategies for associated diseases. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-86 is a selective inhibitor of the NLRP3 inflammasome. This compound demonstrates significant potency in reducing lipopolysaccharide (LPS) and Nigericin-induced lactate dehydrogenase release, with IC50 values of 2.69 μM in THP-1 cells and 1.75 μM in J774A.1 cells. Additionally, NLRP3-IN-86 effectively inhibits gasdermin D cleavage and interleukin-1 beta (IL-1β) secretion, thereby mitigating pyroptosis. This reagent is ideally suited for investigations into inflammatory processes and the underlying mechanisms of pyroptotic cell death. -
NLRP3 Inhibitor
NLRP3-IN-8 is a potent inhibitor of the NLRP3 inflammasome, acting through direct binding with an IC50 of 1.23 μM against IL-1β. This compound demonstrates notable metabolic stability, with a half-life of 138.63 minutes in liver microsomes, and exhibits minimal toxicity, as indicated by an IC50 greater than 100 μM against L02 cells. NLRP3-IN-8 is valuable for research into inflammatory disorders and potential therapeutic interventions targeting the NLRP3 pathway. -
NLRP3 Inhibitor
NLRP3-IN-31 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value in the range of 0.3-0.5 μM. This compound effectively modulates the activation of NLRP3, making it a valuable tool for studying inflammatory pathways. NLRP3-IN-31 can be utilized in research focused on autoinflammatory diseases, metabolic disorders, and neuroinflammation, aiding in the understanding of inflammasome-mediated processes. -
NLRP3 Inhibitor
NLRP3-IN-15 is a selective inhibitor of the NLRP3 inflammasome, targeting the pathway responsible for the activation of pro-inflammatory cytokines. With an IC50 of 0.114 μM, NLRP3-IN-15 effectively inhibits the release of IL-1β, a key mediator in inflammatory responses. This compound is suitable for investigating the role of NLRP3 in various inflammatory disorders and related research applications. -
NLRP3 Inhibitor
NLRP3-IN-69 is a selective inhibitor of the NLRP3 inflammasome, targeting the activation of NF-κB p65. This compound effectively reduces LPS-induced overexpression of pro-inflammatory cytokines including IL-1β, as well as iNOS and COX-2, while inhibiting nitric oxide generation with an IC50 of 5.66 μM. NLRP3-IN-69 serves as a valuable tool in research focused on inflammatory diseases and the modulation of the immune response. -
NLRP3 Inhibitor
NLRP3-IN-62 is a selective inhibitor of the NLRP3 inflammasome, demonstrated to effectively inhibit pyroptosis in THP-1 cells with an IC50 of 0.7 nM. Additionally, it suppresses the release of interleukin-1 beta (IL-1β) with an IC50 of 108.5 nM. This compound serves as a valuable tool for research in inflammation and immune responses, particularly in studies related to diseases involving pyroptotic cell death. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-77 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 5.36 nM in suppressing the viability of THP-1 cells. This compound effectively reduces the secretion of pro-inflammatory cytokines, specifically interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3-IN-77 is a valuable tool for investigating diseases associated with aberrant NLRP3 inflammasome activation, including various cancers and inflammatory disorders. -
NLRP3 Inhibitor
NLRP3-IN-22 is a selective inhibitor of the NLRP3 inflammasome, demonstrating an inhibition rate of 67% at a concentration of 10 μM. This compound is useful for studying the role of NLRP3 in inflammatory processes and can be applied in various research areas, including immunology and disease models related to chronic inflammation. Its selective inhibition makes it a valuable tool for elucidating the mechanisms underlying NLRP3-mediated pathologies. -
NLRP3 Inhibitor
Selnoflast monopotassium is a selective and reversible small molecule inhibitor targeting the NLRP3 inflammasome. It effectively inhibits IL-1β release induced by NLRP3 activation in monocyte-derived macrophages from individuals with Alzheimer's disease. This compound shows significant promise for research applications related to Alzheimer's disease and other systemic inflammatory disorders, including ulcerative colitis and chronic obstructive pulmonary disease. -
COX-2/NLRP3 Inhibitor
COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-38 is a selective inhibitor of the NOD-like receptor protein 3 (NLRP3), known for its role in mediating inflammatory responses through inflammasome activation. With an EC50 value of 23 nM, it effectively reduces the activation of the NLRP3 inflammasome, making it a valuable tool for research into inflammatory diseases. This compound is suited for studies evaluating the modulation of NLRP3-related signaling pathways and the development of therapeutic strategies targeting NLRP3-mediated inflammation. -
NLRP3 Inhibitor
NLRP3-IN-82 is a potent inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of less than 5 nM. This compound demonstrates significant biological activity in the modulation of inflammatory pathways and is applicable in research focused on neurological diseases such as Alzheimer's disease, inflammatory conditions like inflammatory bowel disease, and metabolic disorders including obesity. Its selective inhibition of NLRP3 makes it a valuable tool for studying the underlying mechanisms of these pathologies. -
NLRP3 Inhibitor
NLRP3-IN-14 is a selective inhibitor of the NLRP3 inflammasome, exhibiting a binding affinity (KD) of 5.87 μM. This compound effectively inhibits the release of interleukin-1 beta (IL-1β), with an IC50 value of 0.131 μM. NLRP3-IN-14 is valuable for research into inflammatory processes and the development of therapeutics targeting NLRP3-associated diseases. -
NLRP3 Inhibitor
NLRP3-IN-34 is a potent inhibitor of the NLRP3 inflammasome, targeting its activation and downstream signaling. It effectively inhibits reactive oxygen species (ROS) production and interleukin-1 beta (IL-1β) release, exhibiting an IC50 of 0.48 μM in J774A.1 cells. Additionally, NLRP3-IN-34 has demonstrated the capability to inhibit pyroptosis and exhibits anti-inflammatory effects, particularly in models of dextran sulfate sodium (DSS)-induced peritonitis. This compound is valuable for research focused on inflammation and related disease mechanisms. -
NLRP3 Inhibitor
NLRP3-IN-26 is a specific inhibitor of the NLRP3 inflammasome, demonstrating an IC50 of 0.13 μM. This compound is useful for studying the role of NLRP3 in inflammatory processes and can be applied in models of DSS-induced colitis to elucidate its impact on intestinal inflammation and immune responses. -
NLRP3 Inhibitor
NLRP3-IN-71 is a selective inhibitor of the NLRP3 inflammasome, demonstrating the ability to inhibit IL-1β secretion. This compound is characterized by its blood-brain barrier permeability and oral bioavailability, making it a valuable tool in the study of neurodegenerative diseases and related inflammatory mechanisms. It offers researchers a practical means to investigate the role of NLRP3 in various neurological disorders. -
NLRP3 Inhibitor
JNJ-79883960 is a potent NLRP3 inhibitor, designed to modulate the NLRP3 inflammasome's activity. This compound has demonstrated efficacy in reducing inflammation, making it a valuable tool for investigating inflammatory pathways and associated diseases. Its application includes research into conditions such as autoimmune disorders and chronic inflammatory diseases, providing insights into potential therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-65 is a selective inhibitor of the NLRP3 inflammasome, a key component of the innate immune response. This compound exerts significant biological activity by inhibiting the activation of NLRP3, thereby modulating inflammatory responses. It is valuable for research applications related to autoinflammatory diseases, chronic inflammation, and potential therapeutic strategies aimed at controlling NLRP3-mediated pathways. -
NOD-like Receptor (NLR) Inhibitor
NLRP3-IN-4 is a potent inhibitor of the NOD-like receptor (NLR) NLRP3 inflammasome, exhibiting oral bioavailability. This compound is characterized by its ability to mitigate inflammatory processes, making it particularly relevant for research in inflammatory diseases such as colitis. It is a valuable tool for investigating the role of NLRP3 in immune responses and inflammation modulation. -
NLRP3 Inhibitor
NLRP3-IN-64 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an EC50 of 5 nM for the inhibition of NLRP3 activation. This compound is useful for investigating the role of NLRP3 in inflammatory diseases and provides a valuable tool for research in immune response modulation. Its application extends to studying the mechanisms underlying autoinflammatory conditions and potential therapeutic interventions. -
NLRP3 Inhibitor
Sebrinoflast is a potent NLRP3 inhibitor, exhibiting an IC50 of ≤1 μM for human NLRP3. This compound is valuable in the study of inflammatory conditions and cardiovascular diseases such as non-alcoholic steatohepatitis (NASH) and atherosclerosis. Additionally, it serves as an important tool in neurological disease research, particularly for Alzheimer's disease. -
NLRP3 Inflammasome Inhibitor
NT-0527 is a selective inhibitor of the NLRP3 inflammasome, demonstrating oral bioavailability and effective permeability across the blood-brain barrier. This compound specifically prevents NLRP3 inflammasome formation, leading to decreased maturation and secretion of interleukin-1 beta (IL-1β). NT-0527 exhibits notable anti-inflammatory effects in models of acute inflammation, including the LPS/ATP-induced peritonitis model. It is a valuable tool for research into neuroinflammatory conditions, such as Parkinson's disease and Alzheimer's disease, as well as peripheral inflammatory disorders like type II diabetes and atherosclerosis involving the NLRP3 pathway. -
NOD-like Receptor (NLR) Inhibitor
GSK223 is a quinazolinone compound that acts as a selective inhibitor of the NOD1 pathway. It demonstrates potential anti-inflammatory activity by selectively inhibiting IL-8 release in response to iE-DAP stimulation, while leaving IL-8 secretion unaffected from TNF receptor, TLR2, or NOD2 agonists. Additionally, GSK223 does not directly inhibit RIP2 kinase activity, making it a valuable tool for studying NOD-like receptor signaling and its implications in inflammatory responses. -
NOD-like Receptor (NLR) Inhibitor
NLRP3-IN-53 is a potent inhibitor of the NOD-like receptor NLRP3, exhibiting an IC50 of 3.4 nM. This compound is utilized in research to investigate the roles of the NLRP3 inflammasome in various inflammatory diseases and immune responses. Its selective inhibition helps elucidate the mechanistic pathways involved in NLRP3-related signaling, making it a valuable tool for studying therapeutic targets in the context of autoimmunity and metabolic disorders. -
NLRP3 Inhibitor
NLRP3-IN-58 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 3.85 μM. At a concentration of 10 μM, it effectively reduces IL-1β release by 33%. This compound is valuable for research applications focused on inflammatory pathways and the modulation of innate immune responses. -
NLRP3 Inhibitor
NLRP3-IN-56 is a potent inhibitor of the NLRP3 inflammasome, effectively suppressing IL-1β secretion in THP-1 cells with an IC50 of 9.7 nM. This compound serves as a valuable tool for investigating NLRP3-mediated inflammatory responses and associated pathologies. Its ability to modulate IL-1β levels makes it suitable for research into diseases characterized by NLRP3 activation. -
NLRP3 Inhibitor
NLRP3-IN-28 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an EC50 of 0.07 μM in the inhibition of Nigericin-induced pyroptosis. This compound effectively reduces inflammatory responses in vivo, making it a valuable tool for investigating NLRP3-related diseases and inflammatory pathways. Its application in research provides insights into therapeutic strategies targeting inflammasome activation and related inflammatory conditions. -
Inflammasome Inhibitor
3-Et-3TC is a potent inhibitor of the NLRP3 inflammasome, demonstrating its capacity to modulate inflammasome activation. This compound is valuable for investigating the underlying mechanisms of retinal degenerative diseases and other inflammatory conditions. Its structural modification from Lamivudine enhances its efficacy in biochemical research applications targeting inflammasome pathways. -
PD-L1 Inhibitor
INCB086550 is a potent oral small-molecule inhibitor of PD-L1, exhibiting IC50 values of 3.1, 4.9, and 1.9 nM for human, cynomolgus, and rat PD-L1, respectively. This compound promotes the dimerization of cell-surface PD-L1 and facilitates its entry into Golgi vesicles, leading to nuclear trafficking. INCB086550 is primarily used in cancer research, particularly in studies focusing on immune checkpoint regulation and tumor microenvironment modulation. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN-9 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 3.8 nM. This compound enhances the antitumor activity of immune cells against tumor cells. Additionally, PD-1/PD-L1-IN-9 demonstrates significant in vivo antitumor efficacy in the CT26 mouse model, making it a valuable tool for cancer immunotherapy research. -
PD-L1 Inhibitor
BMS-986189 is a macrocyclic peptide that functions as a highly potent PD-L1 inhibitor, demonstrating an IC50 of 1.03 nM in disrupting the PD-1/PD-L1 interaction. This compound is suitable for cancer research applications, particularly in studies involving human lung carcinoma cells such as L2987, making it valuable for exploring immune checkpoint mechanisms and developing novel therapeutic strategies. -
PD-1/PD-L1 Inhibitor
BMS-8 is a selective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 7.2 μM. It directly binds to PD-L1, promoting the formation of PD-L1 homodimers, thereby obstructing the engagement with PD-1. This compound is primarily utilized in cancer immunotherapy research, particularly in studies focused on the modulation of immune checkpoint pathways. -
PD-1/PD-L1 PPI Inhibitor
Evixapodlin is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 of 0.213 nM. This compound demonstrates significant anticancer and antiviral activities, making it a valuable tool for research in immunotherapy and viral pathogenesis. Evixapodlin is particularly useful for studying the modulation of immune responses in tumor environments and understanding the interplay between immune checkpoints and viral infections. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-14 is a bifunctional inhibitor specifically targeting the PD-1/PD-L1 interaction, exhibiting an IC50 of 27.8 nM. This compound effectively disrupts PD-1/PD-L1 binding while promoting the dimerization, internalization, and degradation of PD-L1. Its unique mechanism of action supports research in immunotherapy and cancer treatment, making it a valuable tool for studies involving immune modulation and T-cell activation. -
PD-L1 Inhibitor
PD-L1-IN-3 is a PD-L1 inhibitor that effectively targets the PD-1/PD-L1 interaction. With an IC50 value of 4.97 nM for inhibiting PD-L1 and an EC50 value of 2.70 μM for Jurkat T cell activation, this compound disrupts PD-1 signaling by binding to the PD-L1 dimer. PD-L1-IN-3 is particularly valuable for research applications in lung cancer and melanoma, facilitating the study of immune checkpoint mechanisms in these diseases. -
PD-1/PD-L1 Inhibitor
MAX-10181 is a selective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 0.018 μM. This compound is instrumental in cancer research, facilitating the exploration of immune checkpoint blockade mechanisms and potential therapeutic applications in oncology and related diseases. Researchers can utilize MAX-10181 to study the modulation of immune responses in various tumor models. -
PD-1/PD-L1 Inhibitor
ARB-272572 is a potent small molecule inhibitor targeting the PD-L1 pathway, exhibiting an IC50 value of 400 pM. This compound enhances antitumor immunity and shows promise in the treatment of chronic viral infections. ARB-272572 is valuable for research applications focused on cancer immunotherapy and viral infection studies. -
PD-1/PD-L1 Inhibitor
N-deacetylated BMS-202 is a potent inhibitor of the PD-1/PD-L1 interaction. This compound plays a significant role in cancer immunotherapy by blocking the immune checkpoint pathway, thereby enhancing T-cell responses against tumor cells. Its application in research encompasses the investigation of tumor microenvironments and the evaluation of immune evasion mechanisms in various cancer types. -
PD-L1/PD-1 Inhibitor
BMS-1001 hydrochloride is an orally active inhibitor of the PD-L1/PD-1 immune checkpoint pathway. It demonstrates low cytotoxicity across various cell lines, making it suitable for research applications. The compound has an IC50 value of 2.25 nM in homogeneous time-resolved fluorescence (HTRF) binding assays, indicating potent inhibition of PD-1 interactions. BMS-1001 is useful for studies focused on cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
ASC-69 is a potent inhibitor of the PD-1/PD-L1 pathway, which plays a critical role in immune evasion by tumors. This small-molecule compound demonstrates strong biological activity in inhibiting the interaction between PD-1 and PD-L1, thereby enhancing T-cell responses against cancer cells. ASC-69 is relevant for research applications focused on cancer immunotherapy and the modulation of immune checkpoint mechanisms. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-33 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 of 6.3 nM. This compound enhances T-cell proliferation, activation, and infiltration into tumor microenvironments, thereby exerting immunomodulatory and anticancer effects. PD-1/PD-L1-IN-33 is applicable in research focused on cancer immunotherapy and the modulation of immune responses. -
PD-L1 Inhibitor
BMS-986238 is an orally active macrocyclic peptide that functions as a PD-L1 inhibitor. This compound exhibits significant anti-tumor activity by blocking the PD-1/PD-L1 interaction, enhancing immune responses against cancer cells. BMS-986238 is utilized in research applications focusing on solid tumors and lymphomas, providing insights into immune checkpoint modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-23 is a potent, orally active inhibitor of the PD-1/PD-L1 interaction. As an ester proagent of L7, a benzo[c][1,2,5]oxadiazole derivative, it has been evaluated for its ability to inhibit PD-L1. This compound demonstrates significant antitumor effects in various tumor models, including syngeneic and PD-L1 humanized mice, making it a valuable tool for cancer research and the development of immune checkpoint therapies. -
PD-L1 Inhibitor
PD-L1-IN-2 is an inhibitor of the programmed death-ligand 1 (PD-L1) pathway, functioning as a potential immunotherapeutic agent against tumors. This Naamidine J derivative demonstrates significant antitumor activity by downregulating PD-L1 expression, thereby enhancing T-cell infiltration and activity within tumors. PD-L1-IN-2 is applicable in preclinical research focused on colorectal cancer and other malignancies where PD-L1 plays a critical role in immune evasion. -
PD-1/PD-L1 Interaction Inhibitor
BMSpep-57 is a competitive macrocyclic peptide inhibitor targeting the PD-1/PD-L1 interaction, exhibiting an IC50 of 7.68 nM. It demonstrates strong binding affinity to PD-L1, with Kd values of 19 nM in Microscale Thermophoresis (MST) and 19.88 nM in Surface Plasmon Resonance (SPR) assays. By disrupting this interaction, BMSpep-57 enhances T cell function, leading to increased IL-2 production in peripheral blood mononuclear cells (PBMCs). This compound is valuable for research applications related to immunotherapy and T cell activation.
